
- BioPharm International's BP Elements, November 2022
- Volume 1
- Issue 11
Shimadzu and UMG Göttingen Enter Analytics Collaboration
The collaboration will see Shimadzu and UMG develop new clinical laboratory methods using LC-MS for TDM analysis.
Shimadzu, a laboratory instruments supplier, and University Medical Center Göttingen (UMG), announced a collaboration to develop new clinical laboratory methods. The focus of their research will be on using liquid chromatography-mass-spectrometry (LC-MS) for therapeutic drug monitoring (TDM) analysis. The collaboration is being performed under Shimadzu’s European Innovation Center program, which is designed to enable collaborations where outside experts can work with Shimadzu technologies.
According to a Oct. 27, 2022 press release, TDM tests, which measure the concentration of drugs currently in blood, have usually been done through an immunoassay, but LC-MS methods have recently grown in popularity due to advantages in strength and accuracy. However, complexity of sample preparation has prevented widespread adoption.
The collaboration will focus on developing Shimadzu's CLAM-2030, a fully automated sample preparation module for LC-MS. The device functions by placing blood collection tubes in position, wherein the module automatically performs sample pretreatment steps up to LC/MS/MS analysis. The collaboration aims to develop new methods for multiple target groups of drugs, as well as means of switching between these new methods easily and quickly.
Source: Shimadzu
Articles in this issue
almost 3 years ago
Considerations for a Successful Reformulation Strategyalmost 3 years ago
Taking a Closer Look at Lipid Nanoparticle Characterizationalmost 3 years ago
Gerresheimer and Nelson Labs NV Announce E&L Partnershipalmost 3 years ago
Lonza and Singzyme Enter Bioconjugates Partnershipalmost 3 years ago
Gilead and MacroGenics Enter $1.7 Billion Oncology Collaborationabout 3 years ago
Merck and Moderna Enter $250 Million Cancer Vaccine Partnershipabout 3 years ago
Alexion, AstraZeneca Acquire Genomic Medicines Companyabout 3 years ago
FDA Expands Oversight of Cell and Gene TherapiesNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.